There was no significant difference in terms of age, total and LDL cholesterol levels, and the proportions of patients with tubulointerstitial nephritis, oral hypoglycemic agent use, statin use, fibrate use, sodium–glucose cotransporter 2 (SGLT2) inhibitor use, and glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among these four subgroups. Here, SLC5A2 is linked to interstitial nephritis.